Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gain Therapeutics (GANX) Gains from Sales and Divestitures (2023 - 2025)

Gain Therapeutics (GANX) has 3 years of Gains from Sales and Divestitures data on record, last reported at $97952.0 in Q3 2025.

  • For Q3 2025, Gains from Sales and Divestitures rose 58.51% year-over-year to $97952.0; the TTM value through Sep 2025 reached $97952.0, up 58.51%, while the annual FY2024 figure was $61794.0, 64.02% down from the prior year.
  • Gains from Sales and Divestitures reached $97952.0 in Q3 2025 per GANX's latest filing, up from $95069.0 in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $171751.0 in Q4 2023 and bottomed at $31125.0 in Q1 2024.
  • Average Gains from Sales and Divestitures over 3 years is $84608.9, with a median of $65629.5 recorded in 2023.
  • Peak YoY movement for Gains from Sales and Divestitures: tumbled 64.02% in 2024, then surged 164.21% in 2025.
  • A 3-year view of Gains from Sales and Divestitures shows it stood at $171751.0 in 2023, then crashed by 64.02% to $61794.0 in 2024, then surged by 58.51% to $97952.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Gains from Sales and Divestitures were $97952.0 in Q3 2025, $95069.0 in Q2 2025, and $63859.0 in Q1 2025.